Experimental myocardial necrosis in rats: role of arjunolic acid on platelet aggregation, coagulation and antioxidant status.
Arjunolic acid, a new triterpene and a potent principle from the bark of Terminalia arjuna, has been shown to provide significant cardiac protection in isoproterenol induced myocardial necrosis in rats. To further explore the mechanism of action of arjunolic acid, antiplatelet activity, anticoagulant assays, electrocardiographic changes, serum marker enzymes, antioxidant status, lipid peroxide and myeloperoxidase (MPO) have been measured and the results are compared with a potent cardioprotective drug, acetyl salicylic acid (ASA). Administration of isoproterenol produces electrocardiographic changes such as decreased R amplitude and increased ST segment elevation and has resulted in an increase in serum marker enzyme levels as well as a decrease in enzymatic and nonenzymatic antioxidant levels. Arjunolic acid at an effective dosage of 15 mg/kg body wt. (pre and post treatment), when administered intraperitoneally (i.p.), effects a decrease in serum enzyme levels and the electrocardiographic changes get restored towards normalcy. Arjunolic acid treatment is also shown to prevent the decrease in the levels of superoxide dismutase, catalase, glutathione peroxidase, ceruloplasmin, alpha-tocopherol, reduced glutathione (GSH), ascorbic acid, lipid peroxide, MPO and the cardioprotection is confirmed by the histopathological studies. This study shows that the cardioprotection of arjunolic acid pre and post treatment could possibly be due to the protective effect against the damage caused by myocardial necrosis.
Sumitra
M
M
Department of Biotechnology, Central Leather Research Institute, Adyar, Chennai, India.
Manikandan
P
P
Kumar
D A
DA
Arutselvan
N
N
Balakrishna
K
K
Manohar
B M
BM
Puvanakrishnan
R
R
D000818:Animals; D000975:Antioxidants / Q000378:metabolism*; D001241:Aspirin / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007545:Isoproterenol / Q000494:pharmacology; D008054:Lipid Peroxides / Q000097:blood / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000473:pathology; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology*; D009336:Necrosis; D010084:Oxidation-Reduction / Q000187:drug effects; D010314:Partial Thromboplastin Time; D009195:Peroxidase / Q000378:metabolism; D010974:Platelet Aggregation / Q000187:drug effects*; D011517:Prothrombin Time; D051381:Rats; D017208:Rats, Wistar; D013917:Thrombin / Q000494:pharmacology; D013918:Thrombin Time; D014197:Trees / Q000737:chemistry; D014315:Triterpenes / Q000737:chemistry / Q000494:pharmacology*
D000975:Antioxidants; D008054:Lipid Peroxides; D014315:Triterpenes; C061640:arjunolic acid; D006861:Hydrogen Peroxide; D009195:Peroxidase; D013917:Thrombin; D007545:Isoproterenol; D001241:Aspirin